Promising results for trial looking at olaparib in combination with bevacizumab as first line treatment

News from the ESMO (European Society for Medical Oncology) 2019 conference: promising results for trial looking at olaparib in combination with bevacizumab as first line treatment.

Comments (0)

Comment (maximum 3500 characters) *

Add a picture

Notify me when someone makes a comment

First name *

Last name *

Email *

Which country do you live in?

Please enter your postcode*

Address line 1

Address line 2

Town or city

Keeping In Touch

We would love to keep you posted with news, activities and how you can help in other ways. We'll never sell or swap your details with anybody else. You are free to change your mind at any time. Please indicate how you are happy to be contacted by using the tick boxes below.

Please note that if you are signing up for an online event being run by our partner Ovarian Cancer Action, the contact details that you provide will be passed on to them, so that they can send you information about your event and keep in touch in the ways that you have indicated that you are happy with.

Via email

Via telephone

Via SMS

Via post

Which country do you live in?

Please enter your postcode*

Address line 1

Address line 2

Town or city

Your Privacy

We will always store your personal details securely. We'll use them to provide the service that you have requested, and communicate with you in the way(s) that you have agreed to. Your data may also be used for analysis purposes, to help us provide the best service possible. For full details see our Privacy Policy

By submitting this form you are agreeing to our terms and conditions

Latest

Risk-reducing mastectomy: the patient's perspective

Ovarian Cancer Action are joined by three women who have had risk reducing mastectomies and made different choice: implant reconstruction, DIEP flap reconstruction, and no reconstruction.
Ranjit Manchanda Population genetic testing - the road travelled and way forward

Ovarian Cancer Action online session with Professor Ranjit Manchanda presenting his research into the viability of population genetic testing.
Hereditary Prostate Cancer: with guests Orchid- Fighting Male Cancer

Ovarian Cancer Action are joined by Orchid- Fighting Male Cancer to discuss hereditary prostate cancer, signs and symptoms and what screening may be available.
Risk-reducing gynaecological surgery: patient perspective

As part of Hereditary Cancer Awareness week, Ovarian Cancer Action's Jo Stanford is joined by a BRCA mutation carrier who has been through risk-reducing surgery to remove her ovaries and fallopian tubes.